Lineage Cell Therapeutics (LCTX) vs ProQR Therapeutics N.V. (PRQR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ProQR Therapeutics N.V. (PRQR) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, losing 33.5% versus a loss of 40.5%. Over five years, LCTX leads with a -56.2% price change compared with -80.1% for PRQR. Lineage Cell Therapeutics is the larger company by market cap ($260.5 million vs $221.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LCTX | PRQR |
|---|---|---|
| Share price | $1.03 | $1.57 |
| Market cap | $260.49M | $221.56M |
| 1-day change | +8.70% | -3.68% |
| YTD return | -38.32% | -22.28% |
| 1-year return | -40.46% | -33.47% |
| 5-year return | -56.17% | -80.08% |
| EPS (TTM) | $-0.19 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.09 | $3.10 |
| 52-week low | $0.88 | $1.33 |
| Distance from 52-week high | -50.72% | -49.35% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +433.98% | +395.54% |
| Average volume | 1.15M | 796.41K |
| Shares outstanding | 252.91M | 141.12M |
| Employees | 72 | 186 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Lineage Cell Therapeutics
LCTX stock →Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
LCTX vs PRQR FAQ
Which is bigger, Lineage Cell Therapeutics or ProQR Therapeutics N.V.?
Lineage Cell Therapeutics (LCTX) is larger, with a market capitalization of $260.49M compared with $221.56M for ProQR Therapeutics N.V. (PRQR).
Which stock has performed better over the past year, LCTX or PRQR?
PRQR returned -33.47% over the past 12 months, compared with -40.46% for LCTX (price return, excluding dividends). Past performance does not predict future results.
Are Lineage Cell Therapeutics and ProQR Therapeutics N.V. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Lineage Cell Therapeutics and Biotechnology: Pharmaceutical Preparations for ProQR Therapeutics N.V..